NCT07135193

Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Athletes

Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Athletes: A Prospective Trial

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: China Medical University Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to evaluate, through a clinical human consumption trial, the effects of taking two capsules (each containing 250 mg of Cordyceps cicadae mycelium, for a total intake of 500 mg per dose) of Grape King Cordyceps cicadae mycelium on visual function and anti-fatigue performance in esports athletes.

Detailed description

This study aims to enroll 12 participants (aged 20-30 years), who are esports players, through oral announcements for recruitment. The anticipated source of participants will be students from the Department of Multimedia Game Development and Applications, Hungkuang University of Science and Technology, second-year and above. On the day prior to the trial, participants will undergo a baseline ophthalmic examination (serving as the control values). Following the baseline assessment, participants will undergo ophthalmic examinations after 1 hour and 2 hours of esports training, respectively, resulting in a total of three measurements. All data will be recorded in the case report form (CRF). On the day of the trial, participants will first undergo an ophthalmic examination. After completion, all 12 participants will be randomly allocated into groups using the QuickCalcs randomization tool (GraphPad Software, https://www.graphpad.com/quickcalcs/randomize1/). Based on the random allocation, capsule packages labeled with codes 001 to 012 will be prepared, containing either the investigational product or placebo. Each package will be distributed to the corresponding participant. Of the 12 participants, 3 will be assigned to the placebo group, and 9 will be assigned to the Cordyceps cicadae mycelium group. Participants will undergo ophthalmic examinations at 1 hour and 2 hours post-administration, and the results will be recorded in the CRF. The investigational product will be in capsule form, containing Cordyceps cicadae mycelium (250 mg per capsule) and excipients, with no other additives. The placebo will have the same excipients and capsule composition, except without the mycelium. Each participant will take a single oral dose on the test day (2 capsules). All investigational products and placebos will be provided by Grape King Bio Ltd.

Conditions

• Visual Acuity
• Accommodation
• Dry Eye

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Cordyceps cicadae	Cordyceps cicadae 500mg
DIETARY_SUPPLEMENT	Blank control	Blank control

Timeline

• Start date: 2025-08-12
• Primary completion: 2025-08-13
• Completion: 2025-12-31
• First posted: 2025-08-21
• Last updated: 2025-08-21

Locations

1 site across 1 country: Taiwan